Co-amorphous formation of piroxicam-citric acid to generate supersaturation and improve skin permeation.

Citric acid Co-amorphous Piroxicam Supersaturation Transdermal drug delivery

Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Mar 2021
Historique:
received: 15 09 2020
revised: 09 11 2020
accepted: 28 11 2020
pubmed: 10 12 2020
medline: 22 6 2021
entrez: 9 12 2020
Statut: ppublish

Résumé

The objective of this study was to prepare a co-amorphous formulation of piroxicam (PIR), a non-steroidal anti-inflammatory drug, and citric acid (CA), and evaluate its skin permeation ability. A spray-drying method was employed to prepare the co-amorphous formulation and its physical properties were characterized. X-ray powder diffraction and thermal analysis confirmed a homogeneous amorphous state, and the infrared spectra revealed intermolecular interactions between PIR and CA, suggesting formation of a co-amorphous formulation of PIR and CA. The PIR-CA co-amorphous formulation exhibited no crystallization for 60 days at 4/25/40°C with silica gel. The PIR-CA co-amorphous formulation increased the solubility of PIR in polyethylene glycol 400 compared with that of the pure drug, and physical mixture (PM) of PIR and CA, confirming a supersaturated state in the formulation. The PIR-CA co-amorphous formulation demonstrated higher skin permeation than PIR alone or PM of PIR and CA, and the flux value was consistent with the degree of saturation. Thus, the increase in the skin permeation of PIR from the PIR-CA co-amorphous formulation directly depended on the increased thermodynamic activity by supersaturation in the absence of interactions between the drug and co-former in the vehicle.

Identifiants

pubmed: 33296711
pii: S0928-0987(20)30455-3
doi: 10.1016/j.ejps.2020.105667
pii:
doi:

Substances chimiques

Excipients 0
Piroxicam 13T4O6VMAM
Citric Acid 2968PHW8QP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105667

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Yuya Hirakawa (Y)

Biologics, Laboratory for Advanced Medicine Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka, 561-0825, Japan; Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan. Electronic address: yuya.hirakawa@shionogi.co.jp.

Hiroshi Ueda (H)

Physical Chemistry, Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka, 561-0825, Japan.

Yusuke Takata (Y)

Physical Chemistry, Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka, 561-0825, Japan.

Kosuke Minamihata (K)

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan.

Rie Wakabayashi (R)

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan.

Noriho Kamiya (N)

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan; Division of Biotechnology, Center for Future Chemistry, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan.

Masahiro Goto (M)

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan; Center for Transdermal Drug Delivery, Kyushu University, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan.

Articles similaires

Humans Psoriasis Lipocalin-2 Keratinocytes Calgranulin B
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation

Classifications MeSH